NEW YORK (GenomeWeb News) — Biosite has not responded to Inverness Medical Innovations' unsolicited offer to buy the company for $90 a share, Inverness said today, although Biosite issued a statement last Thursday saying it had received the offer and was evaluating it.
 
Inverness’s offer came just a week after Biosite agreed to be acquired by Beckman Coulter for $85 a share, or around $1.55 billion.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.